Up‑regulation of lncRNA PXN-AS1-L is associated with unfavorable prognosis in patients suffering from glioma.
Growing evidence has proved that long noncoding RNAs (lncRNAs) act as novel regulators in the progression of various tumors by modulating miRNAs and tumor-related genes. However, the potential function of lncRNA PXN-AS1-L (PXN-AS1-L) in glioma remains unknown. Hence, we aimed to determine whether PXN-AS1-L was dysregulated in glioma and further preliminarily explored its prognostic value in glioma patients. RT-PCR was used for the assessment of PXN-AS1-L levels in glioma tissue and matched normal tissues from our hospital. Chi-square test was applied to explore the possible association between PXN-AS1-L expressions and clinical factors. Kaplan-Meier survival analysis was carried out to determine the influence of PXN-AS1-L expressions on the survival rate of glioma patients. Survival data were further evaluated through univariate and multivariate analyses. PXN-AS1-L levels were differentially upregulated in glioma specimens compared with paired non-tumor specimens. Higher levels of PXN-AS1-L in glioma were observed to be positively associated with WHO grade (p = 0.019), KPS (p = 0.008)and tumor recurrence (p = 0.019). Survival assays revealed that glioma patients with higher PXN-AS1-L expressions had worse overall survival rates. In multivariate analysis, upregulation of PXN-AS1-L expressions (Risk ratio = 2.663, 1.218-4.532, p = 0.014) in glioma tissues was confirmed to be an independent prognostic factor of overall survival in patients. We firstly suggested that PXN-AS1-L was overexpressed in glioma, and could be used as a novel marker of unfavorable outcome in glioma patients.